SUMMARY A better understanding of the mechanism(s) of cell mediated toxicity for colon cells in vitro may help clarify the pathogenesis of inflammatory bowel disease (IBD). We have examined both the cytotoxicity of IBD peripheral blood mononuclear cells and the kinetics ofinduction of such toxicity by soluble plasma factors. Peripheral blood mononuclear cells from IBD patients were found to be cytotoxic for the colon cells. With the use of Chang cells, this cytotoxicity was shown not to be due to an increase in spontaneous cell mediated cytotoxicity. Colon cell toxicity in vitro did not correlate with site of disease or severity, but decreased toxicity appeared to be associated with in vivo steroid administration. Plasma from some IBD patients was capable of inducing normal peripheral blood mononuclear cells to be toxic to colon cells. This ability was not affected by steroid therapy. The inductioncapacityofIBD plasma was not associated with the presence ofcirculating immune complexes, as measured by Raji RIA, suggesting that large complement fixing complexes are not the inducing and directing factors. Unlike findings in other systems, induction could be demonstrated after a one hour preincubation of mononuclear cells with IBD plasma. The kinetics of induction are consistent with the hypothesis that either cytophilic antibody or small circulating immune complexes arm K cells for specific colon cell lysis.
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The many alterations in the reactivity of the cellular and humoral elements of patients with inflammatory bowel disease (IBD) initially led to the hypothesis that the immune system is involved in the pathogenesis of IBD. To date, the most compelling support for this hypothesis remains the demonstration of the in vitro cytotoxicity of IBD peripheral blood lymphocytes (PBL) for trypsinised colon cells.1-3
The precise mechanism of this in vitro cytotoxicity, however, remains poorly defined. Although initial studies suggested that lymphocytes from patients with IBD were intrinsically committed to colon cell lysis,' more recent work suggests that there may be an interaction between uncommitted effector cells and soluble 'arming' factors.45 It has been suggested that the soluble arming factor(s) could be either (I) cytophilic antibodies (CAb) or (2) circulating immune complexes (CIC) having an antibody specificity for colon cell antigens.
Evidence for this hypothesis stems from a number of observations. First, CAb and CIC have been shown to be capable of inducing specific cytotoxicity in other in vitro systems.6 7Second, a previous study has presented some data to suggest that colon cell toxicity induction is produced by a high molecular weight substance, the activity of which is blocked by an anti-immunoglobulin.5 Third, the effector cells in the in vitro reaction apparently possess surface receptors for the Fc portion of immunoglobulins,8 so that either CAb or CIC could theoretically bind to the effector cell and direct its activity. Finally, there is evidence to suggest that CIC occur in patients with IBD,9 10 and that the composition of these complexes may be disease specific.11
The kinetics of induction as presently delineated, There are many factors which influence the demonstration of cytotoxicity, such as the nature of the target cells, effector: target cell ratio, and the duration of the assay. As these assay parameters will also affect the detection of the induction of cytotoxicity, the long induction period previously reported might be an artefact of the assay conditions. Therefore, in the present study we developed a modification of the colon cell cytotoxicity assay to examine the ability of IBD peripheral blood mononuclear cells (PBMC) to produce colon cell toxicity. We were washed thoroughly and kept in suspension with complete medium for two hours. Chromium labelling was performed by incubating 1 X 106 cells with 100,uCi 51Cr for 45 minutes at 37°C. After washing three times in 15 ml of medium, 1 X 105 cells in 150 ,ll complete medium were placed in Eppendorf tubes. Onex 106 PBMC in 150 ,il complete medium were then added and the reaction incubated overnight (10-12 hours) at 37°C. Control tubes containing only target cells in 300 ,ul of complete medium were used to determine spontaneous release. After incubation the tubes were centrifuged at 900 g for 10 minutes and the supernatants counted for released 61Cr by gamma spectro- The PBMC were then washed three times in 15 ml of complete medium, recounted and the final concentration adjusted to yield 1 X 106 PBMC/150 ,l medium. Cytotoxicity against the colon epithelial target cells was assayed as described above. Heat inactivated plasmas without PBMC were also tested in the cytotoxicity assay to determine if plasma carryover might account for colon cell toxicity. Fig. 2 . PBMC from the IBD group were significantly more toxic for the colonic epithelial cells than were PBMC from the control group (P<0 01). As can be seen from Fig. 2 , however, many IBD patients lacked demonstrable cytotoxicity. Subdivision of the IBD patients according to the method of treatment demonstrated that PBMC from patients not receiving corticosteroid therapy were significantly more cytotoxic for colon epithelitum than PBMC from normal controls (P-0 001). In contrast, PBMC from IBD patients receiving corticosteroids did not produce increased cytotoxicity (Fig. 2) . Sulplhasalazine treatment did not appear to produce a similar suppression of cytotoxicity.
Increased PBMC toxicity for coloni epithelium was observed both in patients with ulcerative and granulomatous colonic disease. A patient with granulomatous disease limited to the terminal ileum (by radiographic and sigmoidoscopic examinations) also showed iiicreased cytotoxicity for colon cells.
The increased toxicity of PBMC for colon epithe- The cytotoxicity demonstrated against coloniic epithelial cells by PBMC from untreated IBD patients might have been a reflection of increased nonspecific spontaneous cell mediated cytotoxicity (SCMC). Therefore, we tested PBMC from six healthy controls and nine IBD patients withlout steroid therapy for their ability to lyse Chang liver cells ini vitro. As Table I shows, IBD PBMC, at The results of the induction studies are presented in Fig. 3 . Normal PBMC preincubated for 96 hours with inactivated IBD plasma produced significantly greater colon cell toxicity (P<0-025) than PBMC similarly preincubated with normal allogeneic plasma.
To examine the kinetics of this induction, shorter periods of preincubation of normal PBMC with heat inactivated plasma were performed. These studies demonstrated that PBMC preincubated with IBD plasma for 24 hours also produced significantly greater colon epithelial cell toxicity (p<0-005) than the same PBMC preincubated with normal plasma (Fig. 3) . In fact, as illustrated in the same figure, IBD plasma pretreatment of normal PBMC for as little as one hour resulted in a statistically significant increase in cytotoxicity (P<0-005). It should be noted, however, that heat inactivated IBD plasma, in the absence of PBMC, did not produce colon cell toxicity (Table 2) . Unlike the direct cytotoxicity of inflammatory bowel disease PBMC for colon epithelium, the ability of IBD plasma to induce toxicity was not associated with corticosteroid administration. Furthermore, there was no readily apparent association between disease severity and the ability to induce toxicity.
Four of the IBD plasmas which resulted in PBMC cytotoxic activity were fractionated by Sephadex G-200 column chromatography. The capacity to produce PBMC toxicity for colon epithelial cells eluted in the high molecular weight void volume fractions.
Plasma from 18 IBD patients was examined for both its ability to induce PBMC mediated colon cell toxicity and the presence of CIC by Raji RIA. Only three of 10 plasmas inducing cytotoxicity contained detectable CIC. Furthermore, two plasmas with raised CIC lacked induction capability. Thus, there was no association between the induction of cytotoxicity and the presence of raised levels of Raji detectable immune complexes.
Discussion
The aetiology and pathogenesis of inflammatory bowel disease (IBD) remain unknown. It has been hypothesised that the host immune system is activated, either by external stimuli or by loss of internal suppression, and that it secondarily attacks normal intestinal epithelium. To date the strongest evidence suggesting a role for the immune system in the pathogenesis of IBD has been the demonstration of IBD peripheral blood lymphocyte (PBL) cytotoxicity for trypsinised colon cells in vitro.1-3
In the current study, peripheral blood mono- group.bmj.com on June 28, 2017 -Published by http://gut.bmj.com/ Downloaded from nuclear cells (PBMC) from patients with IBD again produced significantly greater in vitro toxicity for colon epithelial cells than did PBMC from healthy controls. The colon epithelial cells in this study were obtained by mechanical separation and gentle collagenase digestion. Thus, these results not only confirm published findings, but also suggest that the reported cytotoxicity is unrelated to trypsin induced changes in the colon cell surface membrane.
Although the PBMC cytotoxicity for colon cells was significantly increased in the IBD patient group, PBMC from some IBD patients showed no demonstrable cytotoxicity. Patients failing to display cytotoxicity were primarily those receiving corticosteroid therapy, while patients with increased colon cell toxicity were receiving either other forms of therapy or no treatment for their IBD. These data suggest that steroids administered in vivo may block 1BD PBMC toxicity for colon epithelium in vitro. Although the mechanism of this effect was not clearly defined, the above results, coupled with the apparent lack of effect of steroids on induction capabilities of IBD plasma, suggest several potential mechanisms. Steroids may decrease the absolute number of cells capable of undergoing activation, inhibit the ability of lymphocytes to be armed in vivo, or suppress the cytotoxic expression of activated lymphocytes. They apparently do not decrease the production of arming factor(s).
The cytotoxic activity of PBMC did not correlate with the clinical activity of IBD. A similar lack of correlation was reported in a study in which a single individual was followed over a seven month period of variable clinical activity."' The reported loss of cytotoxicity 10 days after resection of diseased bowel3 4 initially appears to be inconsistent with the above findings. However, while those results suggest that diseased bowel must be present for cytotoxicity to be demonstrable, they do not really provide direct evidence regarding the relationship of severity of clinical disease and toxicity of IBD lymphocytes for colon epithelial cells.
It is unclear precisely how the in vitro assays relate to the pathogenesis of IBD. In our study, and in the studies of Shorter et al.' patients with Crohn's disease as well as those with ulcerative colitis had PBMC toxicity for colon epithelial cells in vitro. In fact, PBMC from one of our patients with Crohn's disease limited to the small bowel displayed one of the highest levels of colon cell toxicity. One possible explanation is that the patient with regional enteritis has subclinical disease distal to the small bowel. As clinical methods for detection of disease are relatively crude, a substantial number of patients with no radiographic or sigmoidoscopic evidence of large bowel disease may indeed have mild subclinical colonic involvement. Alternatively, it is possible that the same cytotoxic potential actually occurs in both ulcerative colitis and Crohn's disease but that local cellular or humoral factors alter or regulate the immunological expression in vivo.
The restriction of in vitro colon cell toxicity to lymphocytes obtained from patients with IBD17 has been important in implicating cellular immune responses in the pathogenesis of IBD. However, equally important is the demonstration that such toxicity does not merely reflect a generalised increase in spontaneous cell toxicity for cultured human cells. The lack of toxicity of IBD PBMC for Chang liver cells documented in this study suggests that the cytotoxicity for colon cells is not due to increased SCMC in IBD patients.
The present results indicate that heat inactivated plasma from some IBD patients, though itself not toxic, is capable of inducing normal PBMC to become toxic for colon epithelial cells in culture, after 96 hours of preincubation. Furthermore, some IBD plasmas can also induce toxicity after considerably shorter preincubation periods. These rapid induction results are in contrast with the reports of Perlmann and Broberger ' and Shorter et al.4 We used plasma rather than serum for induction, but this difference is not likely to be responsible for the disparate results. The most likely explanation for the disparity may be the differences in the cytotoxicity assays. The target cells are prepared differently and thus the population of cells, their antigenic determinants and their susceptibility to lysis may be dissimilar. Furthermore, the effector:target cell ratio, a parameter known to be of great importance in in vitro cytotoxicity studies,"' was greater in our experiments than either of the other two investigations. If only a small percentage of the total effector cell population were inducible, the other studies may have had less than optimal 'induced effector': target cell ratios for observing cytotoxicity. Finally, our assay incubation was performed overnight compared with four hours or less in the other studies. As it is known that certain effector cells can make multiple 'hits',"1 20 the increased reaction time may have allowed an amplification phenomenon to occur in our system to produce identifiable cytotoxicity by very few 'induced effector' cells. Studies performed over shorter periods would lack such an amplification and therefore fail to demonstrate toxicity.
The previously demonstrated loss of cytotoxicity after colectomy3 4 is most compatible with CIC activation and direction of normal PBL, as complexes, but not specific antibody or committed T cells, would be expected to disappear rapidly after resection. The high molecular weight of the 'in-ducing substance', as suggested by gel chromatography, is also consistent with immune complex induction of cytotoxicity. To further examine the role of CIC, plasmas examined for the induction of cytotoxicity were also examined for the presence of CIC by a Raji cell radioimmunoassay. This technique, which measures a wide range of complement fixing CIC with considerable sensitivity,2' demonstrated complexes in several patients. However, there was no demonstrable association between the presence of CIC and the induction capabilities of plasma samples.
Complexes which do not activate the complement sequence or are relatively small in size will not be detected by the Raji radioimmunoassay.21 Therefore, while the above data exclude a large population of complexes, they do not preclude the possibility that a particular subset of CIC might be responsible for the induction of cytotoxicity. Further characterisation of the inducing factor should lead to a better understanding of its possible role in the immunopathogenesis of IBD. 
